[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f1IuLnvR8Md9a6G9pQEFz7mNLAQeqmj0oy2k4vTCPmhM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":48,"rows":55},"University of Pisa",[4],111,false,23,5,19138,3,84,[14,17,19,21,23,25,28,30],{"name":15,"count":16},"Periodontitis",7,{"name":18,"count":16},"Periodontal Diseases",{"name":20,"count":9},"Graves Ophthalmopathy",{"name":22,"count":11},"Type 2 Diabetes",{"name":24,"count":11},"Obesity",{"name":26,"count":27},"Hematopoietic Stem Cell Transplantation",2,{"name":29,"count":27},"Benign Prostatic Hyperplasia",{"name":31,"count":27},"STEMI",[33,38,43],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05049603","A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study","2025-12-31","Atorvastatin 20mg",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03098225","A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy","2026-03-31","Methylprednisolone",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07041983","24-h Energy Expenditure and Anti-obesity Medication","2026-06-01","anti obesity medication",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,103,124,145,170,188,214,241,259,285,303,330,355,382,400,418,436,462,490,508,526,561,589,628,646,664,682,700,718,736,754,772,798,826,850,875,902,920,947,973,999],{"intervention":42,"totalTrials":11,"cells":57},{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":78,"PHASE4":80,"NA":91},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":60},[65],{"nctId":66,"briefTitle":67,"status":68,"phases":69,"primaryCompletion":70,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":76},"NCT03110848","Effects of Atorvastatin in Graves' Orbitopathy (GO)","COMPLETED",[51],"2021-04-30","2020-06-01",88,[74,75],"Thyroid Associated Ophthalmopathy","Hypercholesterolemia",[77,42],"Atorvastatin",{"trials":79,"activeCount":60},[],{"trials":81,"activeCount":90,"soonestReadout":41},[82],{"nctId":39,"briefTitle":40,"status":83,"phases":84,"primaryCompletion":41,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":89},"NOT_YET_RECRUITING",[53],"2027-03-31","2024-01-01",120,[74],[42],1,{"trials":92,"activeCount":60},[93],{"nctId":94,"briefTitle":95,"status":68,"phases":96,"primaryCompletion":97,"completion":97,"start":98,"enrollment":99,"conditions":100,"interventions":101},"NCT05345119","Sirolimus in Graves' Orbitopathy",[],"2021-06-15","2020-01-15",30,[20],[102,42],"Sirolimus",{"intervention":37,"totalTrials":90,"cells":104},{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":120,"NA":122},{"trials":106,"activeCount":60},[],{"trials":108,"activeCount":60},[],{"trials":110,"activeCount":60},[],{"trials":112,"activeCount":90,"soonestReadout":36},[113],{"nctId":34,"briefTitle":35,"status":83,"phases":114,"primaryCompletion":36,"completion":115,"start":86,"enrollment":116,"conditions":117,"interventions":119},[52],"2026-12-31",102,[118],"Graves' Orbitopathy",[37],{"trials":121,"activeCount":60},[],{"trials":123,"activeCount":60},[],{"intervention":47,"totalTrials":90,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":127,"activeCount":60},[],{"trials":129,"activeCount":60},[],{"trials":131,"activeCount":60},[],{"trials":133,"activeCount":60},[],{"trials":135,"activeCount":60},[],{"trials":137,"activeCount":90,"soonestReadout":46},[138],{"nctId":44,"briefTitle":45,"status":139,"phases":140,"primaryCompletion":46,"completion":141,"start":142,"enrollment":99,"conditions":143,"interventions":144},"ENROLLING_BY_INVITATION",[],"2026-12-01","2025-07-01",[24],[47],{"intervention":146,"totalTrials":90,"cells":147},"Triptorelin",{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":168},{"trials":149,"activeCount":60},[],{"trials":151,"activeCount":60},[],{"trials":153,"activeCount":60},[],{"trials":155,"activeCount":60},[],{"trials":157,"activeCount":60},[158],{"nctId":159,"briefTitle":160,"status":161,"phases":162,"enrollment":163,"conditions":164,"interventions":166},"NCT00438217","Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children","UNKNOWN",[53],100,[165],"Central Precocious Puberty",[146,167],"Leuprolide",{"trials":169,"activeCount":60},[],{"intervention":167,"totalTrials":90,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":186},{"trials":173,"activeCount":60},[],{"trials":175,"activeCount":60},[],{"trials":177,"activeCount":60},[],{"trials":179,"activeCount":60},[],{"trials":181,"activeCount":60},[182],{"nctId":159,"briefTitle":160,"status":161,"phases":183,"enrollment":163,"conditions":184,"interventions":185},[53],[165],[146,167],{"trials":187,"activeCount":60},[],{"intervention":189,"totalTrials":90,"cells":190},"abciximab",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":212},{"trials":192,"activeCount":60},[],{"trials":194,"activeCount":60},[],{"trials":196,"activeCount":60},[],{"trials":198,"activeCount":60},[],{"trials":200,"activeCount":60},[201],{"nctId":202,"briefTitle":203,"status":68,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT00354406","Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty",[53],"2008-11","2008-12","2006-04",110,[210],"Myocardial Infarction",[189],{"trials":213,"activeCount":60},[],{"intervention":215,"totalTrials":90,"cells":216},"Dapagliflozin 10 MG",{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":239},{"trials":218,"activeCount":60},[],{"trials":220,"activeCount":60},[],{"trials":222,"activeCount":60},[],{"trials":224,"activeCount":60},[],{"trials":226,"activeCount":60},[227],{"nctId":228,"briefTitle":229,"status":161,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":99,"conditions":234,"interventions":237},"NCT04242758","Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy",[53],"2019-12-30","2020-04-01","2019-06-04",[235,236],"Renal Function Disorder","Glucose Metabolism Disorders",[215,238],"Hydrochlorothiazide 12.5mg",{"trials":240,"activeCount":60},[],{"intervention":238,"totalTrials":90,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":257},{"trials":244,"activeCount":60},[],{"trials":246,"activeCount":60},[],{"trials":248,"activeCount":60},[],{"trials":250,"activeCount":60},[],{"trials":252,"activeCount":60},[253],{"nctId":228,"briefTitle":229,"status":161,"phases":254,"primaryCompletion":231,"completion":232,"start":233,"enrollment":99,"conditions":255,"interventions":256},[53],[235,236],[215,238],{"trials":258,"activeCount":60},[],{"intervention":260,"totalTrials":90,"cells":261},"filgrastim",{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":281,"NA":283},{"trials":263,"activeCount":60},[],{"trials":265,"activeCount":60},[],{"trials":267,"activeCount":60},[],{"trials":269,"activeCount":60},[270],{"nctId":271,"briefTitle":272,"status":161,"phases":273,"primaryCompletion":274,"start":275,"enrollment":276,"conditions":277,"interventions":279},"NCT00932217","Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma",[52],"2007-04","2004-12",180,[278],"G-CSF, Multiple Myeloma, Febrile Episode, Filgrastim, Leograstim",[260,280],"lenograstim",{"trials":282,"activeCount":60},[],{"trials":284,"activeCount":60},[],{"intervention":280,"totalTrials":90,"cells":286},{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":299,"NA":301},{"trials":288,"activeCount":60},[],{"trials":290,"activeCount":60},[],{"trials":292,"activeCount":60},[],{"trials":294,"activeCount":60},[295],{"nctId":271,"briefTitle":272,"status":161,"phases":296,"primaryCompletion":274,"start":275,"enrollment":276,"conditions":297,"interventions":298},[52],[278],[260,280],{"trials":300,"activeCount":60},[],{"trials":302,"activeCount":60},[],{"intervention":304,"totalTrials":90,"cells":305},"Proxelan",{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":326,"NA":328},{"trials":307,"activeCount":60},[],{"trials":309,"activeCount":60},[],{"trials":311,"activeCount":60},[],{"trials":313,"activeCount":60},[314],{"nctId":315,"briefTitle":316,"status":161,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":99,"conditions":321,"interventions":325},"NCT03629769","Effects of Proxelan Somministration in Patients With Chronic Prostatitis",[52],"2018-09-01","2018-09-30","2017-02-16",[322,323,324],"Chronic Prostatitis","Chronic Prostatitis With Chronic Pelvic Pain Syndrome","Premature Ejaculation",[304],{"trials":327,"activeCount":60},[],{"trials":329,"activeCount":60},[],{"intervention":331,"totalTrials":90,"cells":332},"Enamel Matrix Derivative application",{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":351,"NA":353},{"trials":334,"activeCount":60},[],{"trials":336,"activeCount":60},[],{"trials":338,"activeCount":60},[],{"trials":340,"activeCount":60},[341],{"nctId":342,"briefTitle":343,"status":161,"phases":344,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":350},"NCT05418621","Does the Non-surgical Application of Enamel Matrix Derivative Reduce the Need of Periodontal Surgical Intervention in Subjects With Severe (Stage III) Periodontitis?",[52],"2024-09","2025-06","2021-03-01",140,[18],[331],{"trials":352,"activeCount":60},[],{"trials":354,"activeCount":60},[],{"intervention":356,"totalTrials":90,"cells":357},"Dapagliflozin 10mg",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":376,"PHASE4":378,"NA":380},{"trials":359,"activeCount":60},[],{"trials":361,"activeCount":60},[],{"trials":363,"activeCount":60},[364],{"nctId":365,"briefTitle":366,"status":68,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":373},"NCT03714594","Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v\u002Fs Saxagliptin or Dapagliflozin in Patients With DM2.",[51],"2022-08-31","2018-07-24",48,[372],"Type2 Diabetes Mellitus",[356,374,375],"Saxagliptin 5mg","Saxagliptin 5mg + Dapagliflozin 10 mg",{"trials":377,"activeCount":60},[],{"trials":379,"activeCount":60},[],{"trials":381,"activeCount":60},[],{"intervention":374,"totalTrials":90,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":394,"PHASE4":396,"NA":398},{"trials":385,"activeCount":60},[],{"trials":387,"activeCount":60},[],{"trials":389,"activeCount":60},[390],{"nctId":365,"briefTitle":366,"status":68,"phases":391,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":392,"interventions":393},[51],[372],[356,374,375],{"trials":395,"activeCount":60},[],{"trials":397,"activeCount":60},[],{"trials":399,"activeCount":60},[],{"intervention":375,"totalTrials":90,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":403,"activeCount":60},[],{"trials":405,"activeCount":60},[],{"trials":407,"activeCount":60},[408],{"nctId":365,"briefTitle":366,"status":68,"phases":409,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":410,"interventions":411},[51],[372],[356,374,375],{"trials":413,"activeCount":60},[],{"trials":415,"activeCount":60},[],{"trials":417,"activeCount":60},[],{"intervention":77,"totalTrials":90,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":421,"activeCount":60},[],{"trials":423,"activeCount":60},[],{"trials":425,"activeCount":60},[426],{"nctId":66,"briefTitle":67,"status":68,"phases":427,"primaryCompletion":70,"completion":70,"start":71,"enrollment":72,"conditions":428,"interventions":429},[51],[74,75],[77,42],{"trials":431,"activeCount":60},[],{"trials":433,"activeCount":60},[],{"trials":435,"activeCount":60},[],{"intervention":437,"totalTrials":90,"cells":438},"Empagliflozin",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":440,"activeCount":60},[],{"trials":442,"activeCount":60},[],{"trials":444,"activeCount":60},[445],{"nctId":446,"briefTitle":447,"status":68,"phases":448,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":455},"NCT03713190","Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).",[51],"2020-02-15","2020-03-15","2018-09-10",25,[454],"End Stage Renal Disease",[437],{"trials":457,"activeCount":60},[],{"trials":459,"activeCount":60},[],{"trials":461,"activeCount":60},[],{"intervention":463,"totalTrials":90,"cells":464},"Metformin",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":484,"PHASE4":486,"NA":488},{"trials":466,"activeCount":60},[],{"trials":468,"activeCount":60},[],{"trials":470,"activeCount":60},[471],{"nctId":472,"briefTitle":473,"status":68,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},"NCT01336322","Metformin and Sitagliptin in Women With Previous Gestational Diabetes",[51],"2017-12","2018-12","2011-05",40,[480],"Pre-diabetes",[463,482,483],"Sitagliptin","Sitagliptin + Metformin",{"trials":485,"activeCount":60},[],{"trials":487,"activeCount":60},[],{"trials":489,"activeCount":60},[],{"intervention":482,"totalTrials":90,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":493,"activeCount":60},[],{"trials":495,"activeCount":60},[],{"trials":497,"activeCount":60},[498],{"nctId":472,"briefTitle":473,"status":68,"phases":499,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":500,"interventions":501},[51],[480],[463,482,483],{"trials":503,"activeCount":60},[],{"trials":505,"activeCount":60},[],{"trials":507,"activeCount":60},[],{"intervention":483,"totalTrials":90,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":511,"activeCount":60},[],{"trials":513,"activeCount":60},[],{"trials":515,"activeCount":60},[516],{"nctId":472,"briefTitle":473,"status":68,"phases":517,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":518,"interventions":519},[51],[480],[463,482,483],{"trials":521,"activeCount":60},[],{"trials":523,"activeCount":60},[],{"trials":525,"activeCount":60},[],{"intervention":527,"totalTrials":27,"cells":528},"Methimazole",{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":547,"NA":549},{"trials":530,"activeCount":60},[],{"trials":532,"activeCount":60},[],{"trials":534,"activeCount":60},[],{"trials":536,"activeCount":60},[537],{"nctId":538,"briefTitle":539,"status":161,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":546},"NCT04776993","A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy",[52],"2024-09-01","2026-03-01","2023-03-02",52,[118],[527],{"trials":548,"activeCount":60},[],{"trials":550,"activeCount":60},[551],{"nctId":552,"briefTitle":553,"status":68,"phases":554,"primaryCompletion":555,"completion":556,"start":557,"enrollment":99,"conditions":558,"interventions":560},"NCT02727738","Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole",[54],"2015-09","2015-12","2014-01",[559],"Graves' Disease",[527],{"intervention":102,"totalTrials":27,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":564,"activeCount":60},[],{"trials":566,"activeCount":60},[],{"trials":568,"activeCount":60},[569],{"nctId":570,"briefTitle":571,"status":161,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":578},"NCT04598815","Sirolimus for Graves' Orbitopathy (GO)",[51],"2024-05-31","2025-05-31","2023-06-01",54,[20],[102],{"trials":580,"activeCount":60},[],{"trials":582,"activeCount":60},[],{"trials":584,"activeCount":60},[585],{"nctId":94,"briefTitle":95,"status":68,"phases":586,"primaryCompletion":97,"completion":97,"start":98,"enrollment":99,"conditions":587,"interventions":588},[],[20],[102,42],{"intervention":590,"totalTrials":90,"cells":591},"Fluorouracil",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":593,"activeCount":60},[],{"trials":595,"activeCount":60},[],{"trials":597,"activeCount":60},[],{"trials":599,"activeCount":60},[],{"trials":601,"activeCount":60},[],{"trials":603,"activeCount":60},[604],{"nctId":605,"briefTitle":606,"status":161,"phases":607,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":611,"interventions":619},"NCT03668418","Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos",[],"2021-05-31","2022-05-31","2018-06-01",[612,613,614,615,616,617,618],"Liver Cancer","Pancreatic Cancer","Gastric Cancer","Esophageal Cancer","Colo-rectal Cancer","Gall Bladder Cancer","Biliary Tract Cancer",[590,620,621,622,623,624,625,626,627],"Lederfolin","Oxaliplatin","Irinotecan","Docetaxel","Cisplatin","Epirubicin","Gemcitabine","Nab paclitaxel",{"intervention":620,"totalTrials":90,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":631,"activeCount":60},[],{"trials":633,"activeCount":60},[],{"trials":635,"activeCount":60},[],{"trials":637,"activeCount":60},[],{"trials":639,"activeCount":60},[],{"trials":641,"activeCount":60},[642],{"nctId":605,"briefTitle":606,"status":161,"phases":643,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":644,"interventions":645},[],[612,613,614,615,616,617,618],[590,620,621,622,623,624,625,626,627],{"intervention":621,"totalTrials":90,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":649,"activeCount":60},[],{"trials":651,"activeCount":60},[],{"trials":653,"activeCount":60},[],{"trials":655,"activeCount":60},[],{"trials":657,"activeCount":60},[],{"trials":659,"activeCount":60},[660],{"nctId":605,"briefTitle":606,"status":161,"phases":661,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":662,"interventions":663},[],[612,613,614,615,616,617,618],[590,620,621,622,623,624,625,626,627],{"intervention":622,"totalTrials":90,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":676},{"trials":667,"activeCount":60},[],{"trials":669,"activeCount":60},[],{"trials":671,"activeCount":60},[],{"trials":673,"activeCount":60},[],{"trials":675,"activeCount":60},[],{"trials":677,"activeCount":60},[678],{"nctId":605,"briefTitle":606,"status":161,"phases":679,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":680,"interventions":681},[],[612,613,614,615,616,617,618],[590,620,621,622,623,624,625,626,627],{"intervention":623,"totalTrials":90,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":690,"PHASE4":692,"NA":694},{"trials":685,"activeCount":60},[],{"trials":687,"activeCount":60},[],{"trials":689,"activeCount":60},[],{"trials":691,"activeCount":60},[],{"trials":693,"activeCount":60},[],{"trials":695,"activeCount":60},[696],{"nctId":605,"briefTitle":606,"status":161,"phases":697,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":698,"interventions":699},[],[612,613,614,615,616,617,618],[590,620,621,622,623,624,625,626,627],{"intervention":624,"totalTrials":90,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":703,"activeCount":60},[],{"trials":705,"activeCount":60},[],{"trials":707,"activeCount":60},[],{"trials":709,"activeCount":60},[],{"trials":711,"activeCount":60},[],{"trials":713,"activeCount":60},[714],{"nctId":605,"briefTitle":606,"status":161,"phases":715,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":716,"interventions":717},[],[612,613,614,615,616,617,618],[590,620,621,622,623,624,625,626,627],{"intervention":625,"totalTrials":90,"cells":719},{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":721,"activeCount":60},[],{"trials":723,"activeCount":60},[],{"trials":725,"activeCount":60},[],{"trials":727,"activeCount":60},[],{"trials":729,"activeCount":60},[],{"trials":731,"activeCount":60},[732],{"nctId":605,"briefTitle":606,"status":161,"phases":733,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":734,"interventions":735},[],[612,613,614,615,616,617,618],[590,620,621,622,623,624,625,626,627],{"intervention":626,"totalTrials":90,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":748},{"trials":739,"activeCount":60},[],{"trials":741,"activeCount":60},[],{"trials":743,"activeCount":60},[],{"trials":745,"activeCount":60},[],{"trials":747,"activeCount":60},[],{"trials":749,"activeCount":60},[750],{"nctId":605,"briefTitle":606,"status":161,"phases":751,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":752,"interventions":753},[],[612,613,614,615,616,617,618],[590,620,621,622,623,624,625,626,627],{"intervention":627,"totalTrials":90,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":766},{"trials":757,"activeCount":60},[],{"trials":759,"activeCount":60},[],{"trials":761,"activeCount":60},[],{"trials":763,"activeCount":60},[],{"trials":765,"activeCount":60},[],{"trials":767,"activeCount":60},[768],{"nctId":605,"briefTitle":606,"status":161,"phases":769,"primaryCompletion":608,"completion":609,"start":610,"enrollment":87,"conditions":770,"interventions":771},[],[612,613,614,615,616,617,618],[590,620,621,622,623,624,625,626,627],{"intervention":773,"totalTrials":90,"cells":774},"Deferasirox",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":785},{"trials":776,"activeCount":60},[],{"trials":778,"activeCount":60},[],{"trials":780,"activeCount":60},[],{"trials":782,"activeCount":60},[],{"trials":784,"activeCount":60},[],{"trials":786,"activeCount":60},[787],{"nctId":788,"briefTitle":789,"status":68,"phases":790,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":797},"NCT04423237","Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT",[],"2024-06-30","2024-12-31","2020-09-30",39,[796],"Iron Overload",[773],{"intervention":799,"totalTrials":90,"cells":800},"oral Prednisone 5mg",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":802,"activeCount":60},[],{"trials":804,"activeCount":60},[],{"trials":806,"activeCount":60},[],{"trials":808,"activeCount":60},[],{"trials":810,"activeCount":60},[],{"trials":812,"activeCount":60},[813],{"nctId":814,"briefTitle":815,"status":161,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":825},"NCT03804723","Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus",[54],"2022-06","2023-09","2019-06",321,[822,823,824],"Systemic Lupus Erythematosus","Glucocorticoids","Therapy Withdrawal",[799],{"intervention":827,"totalTrials":90,"cells":828},"Imatinib\u002FNilotinib",{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":830,"activeCount":60},[],{"trials":832,"activeCount":60},[],{"trials":834,"activeCount":60},[],{"trials":836,"activeCount":60},[],{"trials":838,"activeCount":60},[],{"trials":840,"activeCount":60},[841],{"nctId":842,"briefTitle":843,"status":68,"phases":844,"primaryCompletion":792,"completion":792,"start":845,"enrollment":846,"conditions":847,"interventions":849},"NCT01860456","TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study",[],"2013-05",412,[848],"Chronic Myeloid Leukemia",[827],{"intervention":851,"totalTrials":90,"cells":852},"Selpercatinib",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":854,"activeCount":60},[],{"trials":856,"activeCount":60},[],{"trials":858,"activeCount":60},[],{"trials":860,"activeCount":60},[],{"trials":862,"activeCount":60},[],{"trials":864,"activeCount":60},[865],{"nctId":866,"briefTitle":867,"status":68,"phases":868,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":874},"NCT07543887","Selpercatinib and Body Composition",[],"2026-04-04","2024-04-12",15,[873],"Thyroid Cancer",[851],{"intervention":876,"totalTrials":90,"cells":877},"Empagliflozin \u002F Linagliptin or Dapagliflozin\u002FSaxagliptin Pill",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":879,"activeCount":60},[],{"trials":881,"activeCount":60},[],{"trials":883,"activeCount":60},[],{"trials":885,"activeCount":60},[],{"trials":887,"activeCount":60},[],{"trials":889,"activeCount":60},[890],{"nctId":891,"briefTitle":892,"status":68,"phases":893,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT04735042","SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.",[],"2021-10-07","2022-04-07","2020-10-07",60,[22,899],"Urinary Tract Infections",[876,901],"Empagliflozin or Dapagliflozin Pill",{"intervention":901,"totalTrials":90,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":905,"activeCount":60},[],{"trials":907,"activeCount":60},[],{"trials":909,"activeCount":60},[],{"trials":911,"activeCount":60},[],{"trials":913,"activeCount":60},[],{"trials":915,"activeCount":60},[916],{"nctId":891,"briefTitle":892,"status":68,"phases":917,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":918,"interventions":919},[],[22,899],[876,901],{"intervention":921,"totalTrials":90,"cells":922},"TAC C\u002FD ratio",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":924,"activeCount":60},[],{"trials":926,"activeCount":60},[],{"trials":928,"activeCount":60},[],{"trials":930,"activeCount":60},[],{"trials":932,"activeCount":60},[],{"trials":934,"activeCount":60},[935],{"nctId":936,"briefTitle":937,"status":68,"phases":938,"primaryCompletion":939,"completion":792,"start":940,"enrollment":941,"conditions":942,"interventions":946},"NCT06080490","Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients",[],"2024-09-29","2023-09-29",125,[943,944,945],"Graft Vs Host Disease","Transplant Failure","Stem Cell Transplant Complications",[921],{"intervention":948,"totalTrials":90,"cells":949},"genetic interaction analysis",{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":951,"activeCount":60},[],{"trials":953,"activeCount":60},[],{"trials":955,"activeCount":60},[],{"trials":957,"activeCount":60},[],{"trials":959,"activeCount":60},[],{"trials":961,"activeCount":60},[962],{"nctId":963,"briefTitle":964,"status":68,"phases":965,"primaryCompletion":966,"completion":967,"start":968,"enrollment":969,"conditions":970,"interventions":972},"NCT02329639","Prospective Study of VEGFR-2 \u002FIL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy",[],"2025-10","2026-04","2014-04",307,[971],"Metastatic Breast Cancer",[948],{"intervention":974,"totalTrials":90,"cells":975},"GLP-1",{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":977,"activeCount":60},[],{"trials":979,"activeCount":60},[],{"trials":981,"activeCount":60},[],{"trials":983,"activeCount":60},[],{"trials":985,"activeCount":60},[],{"trials":987,"activeCount":60},[988],{"nctId":989,"briefTitle":990,"status":68,"phases":991,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT03414333","To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.",[54],"2017-06","2018-06","2016-06-29",14,[236,24,997],"Degenerative Brain Disorder",[974],{"intervention":1000,"totalTrials":90,"cells":1001},"Memantine, Dopamine receptor-agonists",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":1003,"activeCount":60},[],{"trials":1005,"activeCount":60},[],{"trials":1007,"activeCount":60},[],{"trials":1009,"activeCount":60},[],{"trials":1011,"activeCount":60},[],{"trials":1013,"activeCount":60},[1014],{"nctId":1015,"briefTitle":1016,"status":68,"phases":1017,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1024},"NCT03918616","P2X7 Receptor, Inflammation and Neurodegenerative Diseases",[],"2018-12-30","2019-03-30","2017-02-20",50,[1023],"Neuro-Degenerative Disease",[1000]]